impact of Allopurinol use on one-year outcome of patients with acute anterior myocardial infarction undergoing PPCI

Published: 28 November 2022| Version 1 | DOI: 10.17632/7d7n2kv7kr.1
Hooman Nateghian, amirhosein ghafouri asbagh


In this clinical trial (IRCT20140512017666N2), 170 patients with anterior STEMI at Shahid Madani Hospital in Tabriz undergoing successful primary angioplasty within 12 hours of the onset of symptoms were included in the study. Patients were randomly divided into two groups of 85 patients receiving allopurinol (intervention group) and receiving the standard protocol (control group). The intervention group received 300 mg of allopurinol before angioplasty and then 100 mg daily for one month after angioplasty. The two groups were then evaluated for in-hospital MACE and followed up for one year for clinical outcomes. Clinical outcomes studied included mortality, stroke, and heart failure. Telephone calls were made to patients in 1-6-12 months. The results of the present study showed that allopurinol administration had no effect on the clinical outcome and one-year complications of patients with STEMI who underwent primary angioplasty.



Tabriz University of Medical Sciences


Health Sciences